Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00781 Entacapone [2] 6, 17
2 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00786 Tolcapone [3] 6, 28, 127
3 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D10825 Opicapone [1] 6
4 MAPK14 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod [2] 113, 222
5 MAPK14 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod [1] 8
6 DDC [6] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse D00558 Carbidopa [7] 6, 13, 17, 90, 140, 164, 201
7 DDC [6] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse D03082 Benserazide [1] 6
8 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
9 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D01044 Flupentixol [1] 97
10 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D07460 Apomorphine [3] 5, 6, 7
11 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D07870 Dopamine [4] 6, 7, 74, 299
12 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D08339 Pergolide [1] 6
13 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D09886 Dexpramipexole [1] 2
14 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D11431 Tavapadon [1] 6
15 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D11839 Foslevodopa [1] 6
16 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
17 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00136 Haloperidol [1] 8
18 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00270 Chlorpromazine [1] 254
19 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00426 Risperidone [5] 8, 156, 179, 187, 206
20 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00454 Olanzapine [2] 2, 8
21 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00560 Pimozide [1] 2
22 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00726 Metoclopramide [2] 46, 51
23 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00987 Cabergoline [3] 6, 74, 75
24 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01044 Flupentixol [1] 97
25 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01164 Aripiprazole [2] 6, 206
26 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01226 Sulpiride [2] 6, 70
27 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01348 Terguride [2] 51, 86
28 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01448 Trifluoperazine [2] 283, 284
29 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01745 Domperidone [5] 6, 13, 17, 51, 230
30 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D02666 Iloperidone [1] 6
31 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D03165 Bromocriptine [2] 6, 74
32 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D05575 Pramipexole [3] 2, 6, 20
33 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D05768 Rotigotine [1] 6
34 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07305 Piribedil [1] 6
35 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07309 Melperone [1] 6
36 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07460 Apomorphine [3] 5, 6, 7
37 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07593 Buspirone [2] 6, 51
38 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07868 Domperidone [5] 6, 13, 17, 51, 230
39 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07870 Dopamine [4] 6, 7, 74, 299
40 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08132 Lisuride [2] 6, 86
41 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08339 Pergolide [1] 6
42 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08456 Quetiapine [2] 6, 13
43 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08489 Ropinirole [4] 2, 6, 74, 309
44 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08590 Tiapride [1] 8
45 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08636 Trifluoperazine [2] 283, 284
46 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09397 Pardoprunox [1] 6
47 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09886 Dexpramipexole [1] 2
48 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09953 Pridopidine [3] 2, 6, 8
49 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09997 Cariprazine [1] 21
50 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D11839 Foslevodopa [1] 6
51 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
52 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00454 Olanzapine [2] 2, 8
53 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D01164 Aripiprazole [2] 6, 206
54 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
55 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07305 Piribedil [1] 6
56 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
57 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride [2] 6, 86
58 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
59 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09397 Pardoprunox [1] 6
60 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
61 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
62 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
63 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00283 Clozapine [1] 6
64 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00454 Olanzapine [2] 2, 8
65 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
66 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
67 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride [2] 6, 86
68 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
69 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
70 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
71 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
72 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
73 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
74 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11431 Tavapadon [1] 6
75 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
76 GRIA1 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
77 GRIA1 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
78 GRIA1 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
79 GRIA1 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
80 GRIA2 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
81 GRIA2 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
82 GRIA2 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
83 GRIA2 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
84 GRIA3 [10] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
85 GRIA3 [10] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
86 GRIA3 [10] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
87 GRIA3 [10] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
88 GRIA4 [7] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
89 GRIA4 [7] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
90 GRIA4 [7] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
91 GRIA4 [7] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
92 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
93 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
94 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
95 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
96 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
97 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
98 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
99 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
100 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
101 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
102 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
103 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
104 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
105 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
106 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
107 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
108 KCNJ3 [8] Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D02910 Amiodarone [2] 28, 127
109 KCNJ5 [7] Retrograde endocannabinoid signaling, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D02910 Amiodarone [2] 28, 127
110 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02561 Moclobemide [1] 6
111 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02579 Iproniazid [1] 6
112 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05458 Phentermine [1] 97
113 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08349 Phenelzine [1] 6
114 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02579 Iproniazid [1] 6
115 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D03731 Selegiline [1] 6
116 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05458 Phentermine [1] 97
117 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08349 Phenelzine [1] 6
118 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08469 Rasagiline [6] 2, 5, 6, 17, 58, 66
119 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10158 Safinamide [2] 6, 17
120 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10829 Rasagiline [6] 2, 5, 6, 17, 58, 66
121 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
122 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
123 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
124 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
125 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [2] 49, 222
126 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
127 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
128 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
129 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
130 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [2] 49, 222
131 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
132 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
133 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
134 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
135 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [2] 49, 222
136 PRKCB [55] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, VEGF signaling pathway, Focal adhesion, Gap junction, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Fc gamma R-mediated phagocytosis, Leukocyte transendothelial migration, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Long-term depression, Inflammatory mediator regulation of TRP channels, Insulin secretion, GnRH signaling pathway, Melanogenesis, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Insulin resistance, Growth hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Leishmaniasis, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Glioma, Non-small cell lung cancer, Hepatocellular carcinoma D11935 Enzastaurin [1] 168
137 MAPK11 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod [2] 113, 222
138 MAPK11 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod [1] 8
139 MAPK13 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod [2] 113, 222
140 MAPK13 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod [1] 8
141 MAPK12 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod [2] 113, 222
142 MAPK12 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod [1] 8
143 SCN1A [1] Dopaminergic synapse D00252 Carbamazepine [3] 6, 13, 231
144 SCN1A [1] Dopaminergic synapse D00354 Lamotrigine [5] 13, 34, 38, 114, 144
145 SCN1A [1] Dopaminergic synapse D00358 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
146 SCN1A [1] Dopaminergic synapse D00512 Phenytoin [1] 13
147 SCN1A [1] Dopaminergic synapse D00533 Oxcarbazepine [1] 13
148 SCN1A [1] Dopaminergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
149 SCN1A [1] Dopaminergic synapse D00538 Zonisamide [1] 6
150 SCN1A [1] Dopaminergic synapse D02910 Amiodarone [2] 28, 127
151 SCN1A [1] Dopaminergic synapse D03492 Cibenzoline [1] 58
152 SCN1A [1] Dopaminergic synapse D05775 Rufinamide [1] 144
153 SCN1A [1] Dopaminergic synapse D07552 Bupivacaine [8] 46, 51, 53, 70, 96, 168, 226, 298
154 SCN1A [1] Dopaminergic synapse D07962 Flecainide [1] 6
155 SCN1A [1] Dopaminergic synapse D08116 Levobupivacaine [1] 46
156 SCN1A [1] Dopaminergic synapse D08127 Lidocaine [13] 6, 13, 22, 34, 46, 51, 70, 84, 86, 107, 168, 226, 256
157 SCN1A [1] Dopaminergic synapse D08215 Mexiletine [5] 1, 2, 10, 113, 114
158 SCN1A [1] Dopaminergic synapse D08319 Oxybuprocaine [1] 6
159 SCN1A [1] Dopaminergic synapse D08458 Quinidine [3] 2, 8, 13
160 SCN1A [1] Dopaminergic synapse D08490 Ropivacaine [4] 22, 36, 46, 70
161 SCN1A [1] Dopaminergic synapse D11155 Eleclazine [1] 58
162 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D03215 Armodafinil [3] 6, 13, 84
163 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D04999 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
164 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D05458 Phentermine [1] 97
165 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D07591 Bupropion [5] 8, 18, 21, 96, 171
166 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D08130 Lisdexamfetamine [1] 13
167 SLC18A2 [4] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08575 Tetrabenazine [1] 8
168 SLC18A2 [4] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10675 Valbenazine [1] 8
169 SLC18A2 [4] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10701 Deutetrabenazine [1] 8
170 CACNA1B [12] MAPK signaling pathway, Synaptic vesicle cycle, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Type II diabetes mellitus, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Nicotine addiction D01173 Cilnidipine [1] 67
171 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
172 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
173 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
174 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
175 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
176 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [4] 58, 96, 140, 167
177 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
178 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
179 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
180 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
181 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226
182 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
183 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
184 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
185 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
186 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
187 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [4] 58, 96, 140, 167
188 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
189 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
190 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
191 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
192 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226